

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Nintedanib for treating interstitial lung disease caused by systemic sclerosis ID1420

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Boehringer Ingelheim (nintedanib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Pulmonary Fibrosis • British Lung Foundation • Muslim Council of Britain • Pulmonary Fibrosis Trust • Scleroderma and Raynaud's UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Respiratory Nurse Specialists • Association of Respiratory Technology and Physiology • British Geriatrics Society • British Society for Rheumatology • British Thoracic Society • Primary Care Respiratory Society UK • Primary Care Rheumatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS North Staffordshire CCG • NHS Redbridge CCG • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (mycophenolate) • Accord-UK (mycophenolate) • Baxter Healthcare (cyclophosphamide) • Novartis Pharmaceuticals UK (mycophenolate) • Roche Products (mycophenolate) • Sandoz (cyclophosphamide, mycophenolate) • Teva Pharma (mycophenolate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Breathing Matters • British Association for Lung Research • Cochrane Airways Group

Provisional matrix for the proposed technology appraisal of nintedanib for treating interstitial lung disease caused by systemic sclerosis ID1420

Issue date: November 2018

© National Institute for Health and Care Excellence 2018. All rights reserved. Page 1 of 3

Appendix A

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none">• Genomics England• MRC Clinical Trials Unit• National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none">• Public Health England• Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.